Study 'brings nuance to the paradigm of precision medicine'

1 July 2019

The precision medicine hypothesis that the genetics of a patient’s cancer will determine their response to a treatment has been thrown into doubt by new research by the UK’s Institute of Cancer Research (ICR).

Cancers with the same genetic weaknesses respond differently to targeted drugs depending on the tumor type of the patient, the research reveals.

"The story isn’t quite as straightforward as matching a drug to a cancer’s genetics"ICR scientists found that cancer cells from a range of tumor types with the same genetic changes sent out different molecular signals when treated with precision medicines – and that this affected how the cells reacted to the treatment.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK